Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
January 25 2024 - 7:30AM
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical
company focused on developing novel medicines for the treatment of
obesity, oncology, and viral induced acute respiratory distress
syndrome, today announced it will host a conference call and audio
webcast on Thursday, February 8, 2024, at 8:00 a.m. ET to discuss
its fiscal 2024 first quarter financial results and to provide a
business update.
The audio webcast will be accessible under the Investors page of
the Company’s website at www.verupharma.com. To join the conference
call via telephone, please dial 1-800-341-1602 (domestic) or
1-412-902-6706 (international) and ask to join the Veru Inc. call.
An archived version of the audio webcast will be available for
replay on the Company’s website for approximately three months. A
telephonic replay will be available on February 8, 2024 at
approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or
1-412-317-0088 (international), passcode 8260066, for one week.
About Veru Inc.Veru is a late clinical stage
biopharmaceutical company focused on developing novel medicines for
the treatment of metabolic diseases, oncology, and ARDS. The
Company’s drug development program includes two late-stage novel
small molecules, enobosarm and sabizabulin.
Enobosarm, a selective androgen receptor modulator (SARM), is
being developed for two indications: (i) Phase 2b clinical study of
enobosarm as a treatment to augment fat loss and to prevent muscle
loss in sarcopenic obese or overweight elderly patients receiving a
GLP-1 RA who are at-risk for developing muscle atrophy and muscle
weakness and (ii) subject to the availability of sufficient
funding, Phase 3 clinical trial of enobosarm for the treatment of
androgen receptor positive (AR+), estrogen receptor positive (ER+)
and human epidermal growth factor receptor 2 negative (HER2-)
metastatic breast cancer in the 2nd line setting.
Sabizabulin, a microtubule disruptor, is being developed as a
Phase 3 clinical trial for the treatment of hospitalized patients
with viral-induced ARDS. The Company does not intend to undertake
further development of sabizabulin for the treatment of
viral-induced ARDS until we obtain funding from government grants,
pharmaceutical company partnerships, or other similar third-party
external sources.
The Company also has an FDA-approved commercial product, the FC2
Female Condom® (Internal Condom), for the dual protection against
unplanned pregnancy and sexually transmitted
infections. Forward-Looking
StatementsThis press release contains "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995, including, without limitation,
express or implied statements related to Veru’s expectations
regarding whether the FDA will accept the enobosarm IND, whether
and when the planned phase 2b trial of enobosarm discussed above
will commence, the planned design, timing, endpoints, patient
population and patient size of such trial and whether such trial
will successfully meet any of its endpoints, whether enobosarm will
meet any unmet need for obesity patients, and whether the Company
will be successful in its transformation into a late stage
biopharmaceutical company focused on obesity and oncology. The
words "anticipate," "believe," "could," "expect," "intend," "may,"
"opportunity," "plan," "predict," "potential," "estimate,"
"should," "will," "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based upon
current plans and strategies of Veru Inc. (the Company) and reflect
the Company's current assessment of the risks and uncertainties
related to its business and are made as of the date of this press
release. The Company assumes no obligation to update any forward-
looking statements contained in this press release because of new
information or future events, developments or circumstances. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and assumptions, and if any such risks or
uncertainties materialize or if any of the assumptions prove
incorrect, our actual results could differ materially from those
expressed or implied by such statements. Factors that may cause
actual results to differ materially from those contemplated by such
forward-looking statements include, but are not limited to,
uncertainties related to market conditions and the satisfaction of
customary closing conditions related to the proposed public
offering and the Company’s expectations regarding the completion,
timing and size of the proposed public offering and the use of
proceeds therefrom. This list is not exhaustive and other risks are
detailed in the Company’s periodic reports filed with the SEC,
including the Company's Form 10-K for the year ended September 30,
2023.
Investor and Media Contact:Samuel FischExecutive Director,
Investor Relations and Corporate CommunicationsEmail:
veruinvestor@verupharma.com
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2024 to May 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From May 2023 to May 2024